SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival

Oncogene

Volumn 30, Issue 49, 2011, Pages 4887-4900

  Fenouille, N ^a,b   Puissant, A ^b,c   Tichet, M ^a,b   Zimniak, G ^a,b   Abbe, P ^a,b   Mallavialle, A ^b,c   Rocchi, S ^a,b,d   Ortonne, J P ^a,b   Deckert, M ^b,c,d   Ballotti, R ^a,b,d   Tartare Deckert, S ^a,b,d  

^a CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c INSERM   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

melanoma; p53; signaling; tumor biology

Indexed keywords

CASPASE 3; CYCLOHEXIMIDE; DACTINOMYCIN; DOXYCYCLINE; OSTEONECTIN; PROTEIN BAX; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; GENE EXPRESSION; HUMAN; HUMAN CELL; MELANOMA CELL; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CELL SURVIVAL; DACTINOMYCIN; GENE KNOCKDOWN TECHNIQUES; HUMANS; MELANOMA; MICE; OSTEONECTIN; OXIDATIVE STRESS; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MDM2; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 82955212970     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.198     Document Type: Article

References (53)

1. Albino AP, Vidal MJ, McNutt NS, Shea CR, Prieto VG, Nanus DM et al. (1994). Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res 4: 35-45. (Pubitemid 24127098)
2. Arnold SA, Brekken RA. (2009). SPARC: a matricellular regulator of tumorigenesis. J Cell Commun Signal 3: 255-273.
3. Ashcroft M, Ludwig RL, Woods DB, Copeland TD, Weber HO, MacRae EJ et al. (2002). Phosphorylation of HDM2 by Akt. Oncogene 21: 1955-1962. (Pubitemid 34270884)
4. Bailet O, Fenouille N, Abbe P, Robert G, Rocchi S, Gonthier N et al. (2009). Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest. Cancer Res 69: 2748-2756.
5. Barker TH, Baneyx G, Cardo-Vila M, Workman GA, Weaver M, Menon PM et al. (2005). SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity. J Biol Chem 280: 36483-36493. (Pubitemid 41633922)
6. Bornstein P, Sage EH. (2002). Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 14: 608-616. (Pubitemid 35247745)
7. Briggs J, Chamboredon S, Castellazzi M, Kerry JA, Bos TJ. (2002). Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene 21: 7077-7091. (Pubitemid 35252982)
8. Chang W, Wei K, Jacobs SS, Upadhyay D, Weill D, Rosen GD. (2010). SPARC suppresses apoptosis of idiopathic pulmonary fibrosis fibroblasts through constitutive activation of beta-catenin. J Biol Chem 285: 8196-8206.
9. Choong ML, Yang H, Lee MA, Lane DP. (2009). Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Cell Cycle 8: 2810-2818.
10. De S, Chen J, Narizhneva NV, Heston W, Brainard J, Sage EH et al. (2003). Molecular pathway for cancer metastasis to bone. J Biol Chem 278: 39044-39050. (Pubitemid 37221807)
11. Fenouille N, Puissant A, Dufies M, Robert G, Jacquel A, Ohanna M et al. (2010). Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC. Cancer Res 70: 9659-9670.
12. Fenouille N, Robert G, Tichet M, Puissant A, Dufies M, Rocchi S et al. (2011). The p53/p21(Cip1/Waf1) pathway mediates the effects of SPARC on melanoma cell cycle progression. Pigment Cell Melanoma Res 24: 219-232.
13. Fukunaga-Kalabis M, Santiago-Walker A, Herlyn M. (2008). Matricellular proteins produced by melanocytes and melanomas: in search for functions. Cancer Microenviron 1: 93-102.
14. Gaggioli C, Deckert M, Robert G, Abbe P, Batoz M, Ehrengruber MU et al. (2005). HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1. Oncogene 24: 1423-1433. (Pubitemid 40343122)
15. Honda R, Tanaka H, Yasuda H. (1997). Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420: 25-27. (Pubitemid 28037193)
16. Horie K, Tsuchihara M, Nakatsura T. (2010). Silencing of secreted protein acidic and rich in cysteine inhibits the growth of human melanoma cells with G arrest induction. Cancer Sci 101: 913-919.
17. Johnson TM, Yu ZX, Ferrans VJ, Lowenstein RA, Finkel T. (1996). Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc Natl Acad Sci USA 93: 11848-11852. (Pubitemid 26347212)
18. Johnstone RW, Ruefli AA, Lowe SW. (2002). Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-164. (Pubitemid 34161136)
19. Khwaja FW, Svoboda P, Reed M, Pohl J, Pyrzynska B, Van Meir EG. (2006). Proteomic identification of the wt-p53-regulated tumor cell secretome. Oncogene 25: 7650-7661. (Pubitemid 44924478)
20. Lavin MF, Gueven N. (2006). The complexity of p53 stabilization and activation. Cell Death Differ 13: 941-950.
21. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, Podhajcer OL. (1997a). The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 108: 210-214. (Pubitemid 27061034)
22. Ledda MF, Adris S, Bravo AI, Kairiyama C, Bover L, Chernajovsky Y et al. (1997b). Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med 3: 171-176. (Pubitemid 27064701)
23. Madhunapantula SV, Robertson GP. (2009). The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res 22: 400-419.
24. Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G. (2006). Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 13: 927-934.
25. Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M. (1999). Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol 30: 339-344. (Pubitemid 29125155)
26. Mayo LD, Donner DB. (2001). A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 98: 11598-11603. (Pubitemid 32928774)
27. Mettouchi A, Cabon F, Montreau N, Vernier P, Mercier G, Blangy D et al. (1994). SPARC and thrombospondin genes are repressed by the c-jun oncogene in rat embryo fibroblasts. EMBO J 13: 5668-5678. (Pubitemid 24363035)
28. Miller AJ, Mihm Jr MC. (2006). Melanoma. N Engl J Med 355: 51-65.
29. Miyashita T, Reed JC. (1995). Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299.
30. Montgomery AM, Reisfeld RA, Cheresh DA. (1994). Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci USA 91: 8856-8860. (Pubitemid 2148815)
31. Nie J, Chang B, Traktuev DO, Sun J, March K, Chan L et al. (2008). IFATS collection: combinatorial peptides identify alpha5beta1 integrin as a receptor for the matricellular protein SPARC on adipose stromal cells. Stem Cells 26: 2735-2745.
32. Nie J, Sage EH. (2009). SPARC functions as an inhibitor of adipogenesis. J Cell Commun Signal 3: 247-254.
33. Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K et al. (2002). Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 277: 21843-21850. (Pubitemid 34952337)
34. Portela M, Casas-Tinto S, Rhiner C, Lopez-Gay JM, Dominguez O, Soldini D et al. (2010). Drosophila SPARC is a self-protective signal expressed by loser cells during cell competition. Dev Cell 19: 562-573.
35. Robert G, Gaggioli C, Bailet O, Chavey C, Abbe P, Aberdam E et al. (2006). SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Res 66: 7516-7523. (Pubitemid 44289206)
36. Sage H, Tupper J, Bramson R. (1986). Endothelial cell injury in vitro is associated with increased secretion of an Mr 43 000 glycoprotein ligand. J Cell Physiol 127: 373-387. (Pubitemid 16065388)
37. Sangaletti S, Di Carlo E, Gariboldi S, Miotti S, Cappetti B, Parenza M et al. (2008). Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. Cancer Res 68: 9050-9059.
38. Schuler M, Green DR. (2001). Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 29: 684-688. (Pubitemid 33131760)
39. Shi Q, Bao S, Maxwell JA, Reese ED, Friedman HS, Bigner DD et al. (2004). Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. J Biol Chem 279: 52200-52209. (Pubitemid 39656594)
40. Shi Q, Bao S, Song L, Wu Q, Bigner DD, Hjelmeland AB et al. (2007). Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene 26: 4084-4094. (Pubitemid 46920166)
41. Smalley KS, Contractor R, Haass NK, Kulp AN, Atilla-Gokcumen GE, Williams DS et al. (2007). An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res 67: 209-217. (Pubitemid 46142777)
42. Smit DJ, Gardiner BB, Sturm RA. (2007). Osteonectin downregulates E-cadherin, induces osteopontin and focal adhesion kinase activity stimulating an invasive melanoma phenotype. Int J Cancer 121: 2653-2660. (Pubitemid 350136408)
43. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X et al. (2001). Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409: 207-211. (Pubitemid 32144287)
44. Soengas MS, Lowe SW. (2003). Apoptosis and melanoma chemore-sistance. Oncogene 22: 3138-3151.
45. Stromblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA. (1996). Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest 98: 426-433. (Pubitemid 26255742)
46. Sturm RA, Satyamoorthy K, Meier F, Gardiner BB, Smit DJ, Vaidya B et al. (2002). Osteonectin/SPARC induction by ectopic beta(3) integrin in human radial growth phase primary melanoma cells. Cancer Res 62: 226-232. (Pubitemid 34074009)
47. Tang MJ, Tai IT. (2007). A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers. J Biol Chem 282: 34457-34467. (Pubitemid 350159487)
48. Tuveson DA, Weber BL, Herlyn M. (2003). BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 4: 95-98. (Pubitemid 37040825)
49. Vogelstein B, Lane D, Levine AJ. (2000). Surfing the p53 network. Nature 408: 307-310.
50. Weaver MS, Workman G, Sage EH. (2008). The copper binding domain of SPARC mediates cell survival in vitro via interaction with integrin beta1 and activation of integrin-linked kinase. J Biol Chem 283: 22826-22837.
51. Weiss J, Schwechheimer K, Cavenee WK, Herlyn M, Arden KC. (1993). Mutation and expression of the p53 gene in malignant melanoma cell lines. Int J Cancer 54: 693-699. (Pubitemid 23188204)
52. Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, Berkowitz RS et al. (2001). SPARC (secreted protein acidic and rich in cysteine)induces apoptosis in ovarian cancer cells. Am J Pathol 159: 609-622. (Pubitemid 32751091)
53. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. (2001). HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phos-phorylation. Nat Cell Biol 3: 973-982. (Pubitemid 34428742)